The Motley Fool

Think fast! A FTSE 100 stock I think you need to buy in the next 7 days

Image source: Getty Images.

I’d expected Safestore to get 2020 off to a flyer with some strong trading details today. And I’m pleased to say I wasn’t left disappointed. It’s not the only exciting growth share that should cheer the market with brilliant financials, however.

I’m certainly expecting a sunny set of trading numbers when Smith & Nephew (LSE: SN) unveils full-year results a week from today (20 February). A string of positive updates helped the medical giant rise 25% in value in 2019. And I reckon that upcoming statement could help it get up and running for 2020.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Smith & Nephew, a world leader in the business of artificial joints and limbs, and increasingly influential in the fast-growing surgical robotics market, certainly impressed market makers last time out in October.

It then advised that third-quarter underlying revenues increased 4% year-on-year. This was up from 3.5% in the prior three months and sprinted past broker expectations. And full-year sales growth guidance was upgraded to between 3.5% and 4.5%.

Sales accelerate

Smith & Nephew witnessed accelerating momentum across the business in the last reported quarter, with sales rising across all three major units (Orthopaedics, Advanced Wound Management and Sports Medicine & ENT) on an annual basis. Sales across the latter division have been particularly impressive of late. Like-for-like revenue growth of 5.4% here in the first half of 2019 leapt to an even-better 6.9% in quarter three.

Solid uptake of its shoulder repair products in the US has helped to underpin strong progress here. The States are responsible for almost half of group sales, making it the company’s single largest region by turnover. Robust market conditions here are allowing it to offset temporary weakness in its other so-called Established Markets.

What makes me really excited, though, is the rate at which Smith & Nephew’s product is being adopted in its Emerging Markets, and in particular in China. The Footsie business is benefitting from turbocharged healthcare investment in these regions and underlying revenues rocketed 16% year-on-year.

M&A monster

Its rising might in developing territories is only one reason why I’m backing Smith & Nephew to thrive over the next decade. I’m also encouraged by the impact its bold approach to acquisitions is having.

Headline revenues rose 6.5% in the third quarter, a contribution of 3.9% from recent M&A action helping to offset 140 basis points worth of exchange rate headwinds. Terrific acquisitions (like that of regenerative medicine specialist Osiris Therapeutics last April) are allowing it to capitalise on fast-growing and/or underutilised markets. And it has no intention of slowing down. Last month, it bought California’s Tusker Medical, a manufacturer of tympanostomy tubes for the treatment of ear complaints.

City analysts are expecting Smith & Nephew to record meaty profits growth of 8% in 2020 and 9% in 2021. And I’m backing the bottom line to keep ballooning over the next decade. It’s a share fully worthy of a premium P/E ratio of 21.7 times, in my opinion.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.